...have their own advantages because accessing an innovative asset is often inexpensive, and “there’s a galaxy...

...TopTaiwan; KGI VC; Ta Ya Venture Capital; Milestone Capital; Daiwa Corporate Investment Co. Ltd.; China Galaxy...

...included TopTaiwan, KGI VC, Ta Ya Ventures, Milestone Capital, Daiwa Taiwan-Japan Biotech Fund and China Galaxy...

...Interpace said Galaxy Health Network will cover all of Interpace’s molecular pathology tests and services. Interpace’s...
...Galaxy Health covers more than 3.5 million lives. Interpace Diagnostics Group Inc. (NASDAQ:IDXG), Parsippany, N.J. Galaxy...

...notes that FDA requires 12-month stability data Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Terminates the Phase III GALAXY-2...

...Pharma Pvt. Ltd. CRD1152 Indoleamine 2,3-dioxygenase (INDO; IDO); tryptophan 2,3-dioxygenase (TDO2; TDO) Preclin Not started Galaxy Biotech LLC...

...Partners Joe Pantginis Downgrade Neutral (from buy) Peaker downgraded after Synta terminated the Phase III GALAXY-2...

...Synta discontinued the open-label, international Phase III GALAXY-2 trial in about 850 patients with stage IIIB/IV...

...NASDAQ:SNTA) sank $1.30 (64%) to $0.74 after it said it will terminate the Phase III GALAXY-2...
...data from the studies next year. Synta said there were no new safety signals in GALAXY-2...

...to start this year (see BioCentury, March 17). Ganetespib also is in the Phase III GALAXY-2...